临床试验/NCT02802241

NCT02802241已完成不适用

Effects of Open-label vs Double-blind Treatment in IBS.

Beth Israel Deaconess Medical Center1 个研究点分布在 1 个国家目标入组 340 人开始时间: 2016年6月最近更新: 2024年1月22日

适应症

干预措施

试验速览

阶段: 不适用
状态: 已完成
发起方: Beth Israel Deaconess Medical Center
入组人数: 340
试验地点: 1
主要终点: Change in Irritable Bowel Syndrome - Symptom Severity Score (IBS-SSS) From Baseline to Six Weeks.

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

The purpose of this study is to investigate placebo effects and peppermint oil in Irritable Bowel Syndrome.

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Parallel
主要目的: Treatment

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Meet Rome IV diagnostic criteria for IBS

排除标准

未提供

研究组 & 干预措施

open-label placebo

Experimental

干预措施: placebo (Drug)

double-blind placebo

Experimental

干预措施: placebo (Drug)

double-blind peppermint oil

Experimental

干预措施: peppermint oil (Dietary Supplement)

结局指标

主要结局

Change in Irritable Bowel Syndrome - Symptom Severity Score (IBS-SSS) From Baseline to Six Weeks.

时间窗: 6 weeks

Score ranges from 0-500, 0 indicates no symptoms, 500 indicates worst possible symptoms

次要结局

未报告次要终点

研究者

发起方

Beth Israel Deaconess Medical Center

申办方类型

Other

责任方

Principal Investigator

主要研究者

Judy Nee

Assistant Professor of Medicine

Beth Israel Deaconess Medical Center

研究点 (1)

Loading locations...

相似试验

已完成

3 期

Clinical Effectiveness of Enteric Coated(E.C.) Anise-oil on Irritable Bowel SyndromeIrritable Bowel Syndrome

NCT02364830Shiraz University of Medical Sciences120

已完成

2 期

Efficacy of Mesalamine in Diarrhea-predominant Irritable Bowel Syndrome (dIBS)Irritable Bowel Syndrome

NCT01327300University of Florida7

已完成

2 期

Study to Evaluate the Efficacy, Safety, and Tolerability of BOS-589 in the Treatment of Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)Diarrhea-predominant Irritable Bowel Syndrome

NCT03977155Boston Pharmaceuticals133

已完成

不适用

To Evaluate the Safety and Efficacy of Pediococcus Acidilactici PA53 in Relieving Constipation in AdultsConstipation

NCT06761443Wecare Probiotics Co., Ltd.87

已完成

1 期

Safety Assessment of Potential Interactions Between IV Methamphetamine and Osmotic-Release Methylphenidate (OROS-MPH)Methamphetamine DependenceMethamphetamine Abuse

NCT00603434University of Cincinnati16